Clinical Trial: NCT04919811
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Nuvation Bio Inc. |
| Information Provided By: | Nuvation Bio Inc. |
| Last Update Posted: | 2026-01-07 |
Study Overview
Brief Summary
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Official Title
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Conditions
Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Taletrectinib
Other Study ID Numbers
- AB-106-G208
Start Date (Actual)
2021-09-01
Primary Completion Date (Actual)
2025-06-11
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
217
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Nuvation Bio Inc. |
| Information Provided By: | Nuvation Bio Inc. |
| Last Update Posted: | 2026-01-07 |
Study Overview
Brief Summary
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Official Title
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Conditions
Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Taletrectinib
Other Study ID Numbers
- AB-106-G208
Start Date (Actual)
2021-09-01
Primary Completion Date (Actual)
2025-06-11
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
217
Study Type
Interventional
Phase
Phase 2